Melpida by Elpida Therapeutics for Paraplegia: Likelihood of Approval
Melpida is under clinical development by Elpida Therapeutics and currently in Phase II for Paraplegia. According to GlobalData, Phase II drugs for Paraplegia does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Melpida LoA Report. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.Melpida overviewMelpida is under development for the treatment of spastic paraplegia type 50 (SPG50). The therapeutic candidate comprises recombinant adeno-associated virus (serotype 9) encoding a codon optimized human AP4M1 transgene (hAP4M1opt). It is administered through intrathecal route.Elpida Therapeutics overviewElpida Therapeutics is a biotechnology research company that delivers gene therapies to patients and offers toxicology plasmid, clinical trials, cell culture and cell therapy products. The company is headquartered in Los Angeles, California, the US. For a complete picture of Melpida's drug-specific PTSR and LoA scores, buy the report here.
What's Your Reaction?
